Catalyst Pharmaceuticals to License North American Rights to

Vamorolone is Currently Under Review with the FDA for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone... | June 20, 2023

Related Keywords

Mexico , Japan , Switzerland , France , United States , Canada , United Kingdom , Swiss , America , American , Patrickj Mcenany , , European Medicines Agency , Santhera Pharmaceuticals , Health Canada , Regulatory Agency , Catalyst Pharmaceuticals , Steering Committee , Moelis Company , Development Rights For Vamorolone , Santhera Pharmaceuticals Holding , Drug Administration , Catalyst Pharmaceuticals Inc , Life Science Alliance , Chiesi Group , Japan Should Santhera Pursue Partnership Opportunities , Currently Under Review , Duchenne Muscular Dystrophy , Rare Neuromuscular , Granted Fast Track , Orphan Drug Designation , Treat Duchenne Muscular , Launch Vamorolone , Regulatory Approval , Include Commercial , Future Development Rights , Additional Indications , North America , First Negotiation , Japan Should Santhera Pursue Partnership , Also Includes , Strategic Equity Investment , North American , New Drug Application , Prescription Drug User Fee Act , Orphan Drug , Fast Track , Rare Pediatric Disease , Joint Steering Committee , Promising Innovative Medicine , Proc Natl Acad Sci United States , United Kingdom Medicines , Full Prescribing , Safety Information , Full Prescribing Information ,